Biogen (BIIB) director receives 1,505 restricted stock units in grant

Rhea-AI Filing Summary

SHERWIN STEPHEN A reported acquisition or exercise transactions in this Form 4 filing.

Biogen Inc. director Stephen A. Sherwin reported receiving an equity award of 1,505 shares of common stock on June 9, 2026, at no cash cost to him, as a grant or award. Following this grant, he holds a total of 15,193 common shares directly.

The award consists of restricted stock units that will vest on the earlier of the next annual meeting or the anniversary of the June 9, 2026 grant date, tying the compensation to his continued board service over this period.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider SHERWIN STEPHEN A

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,505	$0.00	--

Holdings After Transaction: Common Stock — 15,193 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Equity award size: 1,505 shares Grant price: $0.0000 per share Post-transaction holdings: 15,193 shares +2 more

5 metrics

Equity award size 1,505 shares Grant of Biogen common stock on June 9, 2026

Grant price $0.0000 per share Compensation grant, not open-market purchase

Post-transaction holdings 15,193 shares Total Biogen common shares held directly after grant

Transaction code A Grant, award, or other acquisition of common stock

Vesting condition Earlier of next annual meeting or June 9, 2026 anniversary Restricted stock units vesting terms

Key Terms

restricted stock units, annual meeting, grant, award, or other acquisition, beneficial ownership

4 terms

restricted stock units financial

"The restricted stock units vest on the earlier of (i) the next annual meeting..."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

annual meeting financial

"The restricted stock units vest on the earlier of (i) the next annual meeting..."

A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.

grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

beneficial ownership financial

"represents his reported beneficial ownership following the June 9, 2026 transaction"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SHERWIN STEPHEN A

(Last) (First) (Middle)

BIOGEN INC.

225 BINNEY STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOGEN INC. [ BIIB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/09/2026		A		1,505(1)	A	$0	15,193	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted stock units vest on the earlier of (i) the next annual meeting or (ii) the anniversary of the date of grant of June 9, 2026.

	/s/ Wendell Taylor, Attorney in Fact for Stephen Sherwin	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Biogen (BIIB) director Stephen Sherwin report?

Stephen A. Sherwin reported an equity award of 1,505 shares of Biogen common stock. The filing classifies it as a grant or award acquisition, meaning compensation rather than an open-market purchase, and the shares were received at no stated cash price per share.

When do Stephen Sherwin’s Biogen restricted stock units vest?

The restricted stock units vest on the earlier of the next annual meeting or the anniversary of the June 9, 2026 grant date. This schedule links vesting to Sherwin’s continued board service through the company’s normal governance cycle.

How many Biogen shares does Stephen Sherwin hold after this Form 4 transaction?

After the reported grant of 1,505 shares, Stephen A. Sherwin holds 15,193 Biogen common shares directly. This total includes the new award and represents his reported beneficial ownership following the June 9, 2026 transaction.

Was Stephen Sherwin’s recent Biogen equity award an open-market stock purchase?

No. The transaction is coded as “A” for grant, award, or other acquisition, with a price of $0.0000 per share. This indicates it is compensation-related rather than an open-market purchase of Biogen stock by Sherwin.

Does Stephen Sherwin’s Biogen Form 4 include any option exercises or derivative trades?

No derivative transactions are reported in this Form 4. The filing shows only a non-derivative acquisition of 1,505 Biogen common shares as a grant or award, and the derivative section of the summary contains no remaining option or similar positions.